Brokerages Anticipate Tango Therapeutics, Inc. (NASDAQ:TNGX) Will Post Quarterly Sales of $5.97 Million

Analysts predict that Tango Therapeutics, Inc. (NASDAQ:TNGXGet Rating) will post $5.97 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Tango Therapeutics’ earnings, with estimates ranging from $5.80 million to $6.13 million. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Tango Therapeutics will report full year sales of $23.57 million for the current financial year, with estimates ranging from $23.00 million to $24.13 million. For the next financial year, analysts anticipate that the business will report sales of $23.75 million, with estimates ranging from $23.00 million to $24.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Tango Therapeutics.

Tango Therapeutics (NASDAQ:TNGXGet Rating) last released its quarterly earnings results on Monday, March 28th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $5.72 million for the quarter, compared to the consensus estimate of $6.12 million.

Separately, Zacks Investment Research raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research report on Wednesday, April 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $13.75.

NASDAQ:TNGX opened at $5.57 on Monday. Tango Therapeutics has a 52 week low of $4.41 and a 52 week high of $18.84. The firm’s 50-day simple moving average is $7.04 and its 200 day simple moving average is $8.92.

A number of hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. bought a new position in Tango Therapeutics in the 3rd quarter valued at about $41,000. Royal Bank of Canada bought a new stake in shares of Tango Therapeutics during the 1st quarter valued at approximately $32,000. Marshall Wace LLP bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at approximately $68,000. Swiss National Bank grew its holdings in shares of Tango Therapeutics by 7.4% during the 1st quarter. Swiss National Bank now owns 93,100 shares of the company’s stock valued at $706,000 after purchasing an additional 6,400 shares during the last quarter. Finally, Penserra Capital Management LLC bought a new stake in shares of Tango Therapeutics during the 3rd quarter valued at approximately $133,000. 77.28% of the stock is currently owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile (Get Rating)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Read More

Get a free copy of the Zacks research report on Tango Therapeutics (TNGX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Tango Therapeutics (NASDAQ:TNGX)

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with's FREE daily email newsletter.